Treatment of primary liver graft nonfunction with prostaglandin E1

Paul D. Greig, Graham M. Woolf, Stephen B. Sinclair, Michael Abecassis, Steven M. Strasberg, Bryce R. Taylor, Laurence M. Blendis, Riccardo A. Superina, Michael F X Glynn, Bernard Langer, Gary A. Levy*

*Corresponding author for this work

Research output: Contribution to journalArticle

218 Citations (Scopus)

Abstract

Primary nonfunction following orthotopic liver transplantation is characterized by rapidly rising serum transaminases, minimal bile production, and severe coagulopathy, which can progress to hypoglycemia, hepatic encephalopathy, and acute renal failure. Untreated it has a mortality of over 80% and to date the only treatment has been retransplantation. As a result of the beneficial effect of Prostaglandin infusion in patients with fulminant hepatic failure, this trial was conducted to determine whether PGE1 would be of value in primary nonfunction. We have encountered 16 cases of primary nonfunction in 94 liver transplants, an incidence of 17%. Initially in the program, there were 6 occurrences of nonfunction that did not receive PGEi; 3 underwent retransplantation (2 survivors), 2 died awaiting another liver, and in one recovery of hepatocellular function occurred with supportive care but the patient died of cytomegalovirus infection. Ten patients received PGE1 within 4—34 hr of transplantation. Within 12 hr of treatment, 8 patients responded with a significant fall in the AST (129 U/hr) whereas, in the untreated group, the AST continued to rise (267±102 U/hr) at the same rate as prediagnosis (337±95 U/hr). At the conclusion of the infusion (4—7 days) in the 8 responders, there were significant decreases in AST (4386±546 U/L to 102±21 U/L), prothrombin time (22± 2 to 12±.4 sec) and partial thromboplastin time (4 5 ± 3 - 2 9± 4 sec), and significant increases in coagulation factor V (26±8 to 95±12%) and factor VII (10±5 to 61± 4%). No serious side effects occurred, although 2 patients developed diarrhea, and abdominal cramps. Two patients treated with PGEX were retransplanted at 1 0 - 36 hr and were considered nonresponders. Graft survival was 80% in the PGEi-treated group and 17% in the untreated group (P<0.05) and patient survival was 90% and 33%, respectively. This study suggests a potential benefit of PGEi in the treatment of primary nonfunction.

Original languageEnglish (US)
Pages (from-to)447-453
Number of pages7
JournalTransplantation
Volume48
Issue number3
StatePublished - Jan 1 1989

Fingerprint

Alprostadil
Transplants
Liver
Therapeutics
Factor VII
Factor V
Colic
Hepatic Encephalopathy
Partial Thromboplastin Time
Acute Liver Failure
Prothrombin Time
Recovery of Function
Cytomegalovirus Infections
Graft Survival
Transaminases
Hypoglycemia
Acute Kidney Injury
Bile
Liver Transplantation
Prostaglandins

ASJC Scopus subject areas

  • Transplantation

Cite this

Greig, P. D., Woolf, G. M., Sinclair, S. B., Abecassis, M., Strasberg, S. M., Taylor, B. R., ... Levy, G. A. (1989). Treatment of primary liver graft nonfunction with prostaglandin E1 Transplantation, 48(3), 447-453.
Greig, Paul D. ; Woolf, Graham M. ; Sinclair, Stephen B. ; Abecassis, Michael ; Strasberg, Steven M. ; Taylor, Bryce R. ; Blendis, Laurence M. ; Superina, Riccardo A. ; Glynn, Michael F X ; Langer, Bernard ; Levy, Gary A. / Treatment of primary liver graft nonfunction with prostaglandin E1 In: Transplantation. 1989 ; Vol. 48, No. 3. pp. 447-453.
@article{5be643fbb9ad4b85b452558a8b48adf4,
title = "Treatment of primary liver graft nonfunction with prostaglandin E1",
abstract = "Primary nonfunction following orthotopic liver transplantation is characterized by rapidly rising serum transaminases, minimal bile production, and severe coagulopathy, which can progress to hypoglycemia, hepatic encephalopathy, and acute renal failure. Untreated it has a mortality of over 80{\%} and to date the only treatment has been retransplantation. As a result of the beneficial effect of Prostaglandin infusion in patients with fulminant hepatic failure, this trial was conducted to determine whether PGE1 would be of value in primary nonfunction. We have encountered 16 cases of primary nonfunction in 94 liver transplants, an incidence of 17{\%}. Initially in the program, there were 6 occurrences of nonfunction that did not receive PGEi; 3 underwent retransplantation (2 survivors), 2 died awaiting another liver, and in one recovery of hepatocellular function occurred with supportive care but the patient died of cytomegalovirus infection. Ten patients received PGE1 within 4—34 hr of transplantation. Within 12 hr of treatment, 8 patients responded with a significant fall in the AST (129 U/hr) whereas, in the untreated group, the AST continued to rise (267±102 U/hr) at the same rate as prediagnosis (337±95 U/hr). At the conclusion of the infusion (4—7 days) in the 8 responders, there were significant decreases in AST (4386±546 U/L to 102±21 U/L), prothrombin time (22± 2 to 12±.4 sec) and partial thromboplastin time (4 5 ± 3 - 2 9± 4 sec), and significant increases in coagulation factor V (26±8 to 95±12{\%}) and factor VII (10±5 to 61± 4{\%}). No serious side effects occurred, although 2 patients developed diarrhea, and abdominal cramps. Two patients treated with PGEX were retransplanted at 1 0 - 36 hr and were considered nonresponders. Graft survival was 80{\%} in the PGEi-treated group and 17{\%} in the untreated group (P<0.05) and patient survival was 90{\%} and 33{\%}, respectively. This study suggests a potential benefit of PGEi in the treatment of primary nonfunction.",
author = "Greig, {Paul D.} and Woolf, {Graham M.} and Sinclair, {Stephen B.} and Michael Abecassis and Strasberg, {Steven M.} and Taylor, {Bryce R.} and Blendis, {Laurence M.} and Superina, {Riccardo A.} and Glynn, {Michael F X} and Bernard Langer and Levy, {Gary A.}",
year = "1989",
month = "1",
day = "1",
language = "English (US)",
volume = "48",
pages = "447--453",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

Greig, PD, Woolf, GM, Sinclair, SB, Abecassis, M, Strasberg, SM, Taylor, BR, Blendis, LM, Superina, RA, Glynn, MFX, Langer, B & Levy, GA 1989, 'Treatment of primary liver graft nonfunction with prostaglandin E1 ', Transplantation, vol. 48, no. 3, pp. 447-453.

Treatment of primary liver graft nonfunction with prostaglandin E1 . / Greig, Paul D.; Woolf, Graham M.; Sinclair, Stephen B.; Abecassis, Michael; Strasberg, Steven M.; Taylor, Bryce R.; Blendis, Laurence M.; Superina, Riccardo A.; Glynn, Michael F X; Langer, Bernard; Levy, Gary A.

In: Transplantation, Vol. 48, No. 3, 01.01.1989, p. 447-453.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Treatment of primary liver graft nonfunction with prostaglandin E1

AU - Greig, Paul D.

AU - Woolf, Graham M.

AU - Sinclair, Stephen B.

AU - Abecassis, Michael

AU - Strasberg, Steven M.

AU - Taylor, Bryce R.

AU - Blendis, Laurence M.

AU - Superina, Riccardo A.

AU - Glynn, Michael F X

AU - Langer, Bernard

AU - Levy, Gary A.

PY - 1989/1/1

Y1 - 1989/1/1

N2 - Primary nonfunction following orthotopic liver transplantation is characterized by rapidly rising serum transaminases, minimal bile production, and severe coagulopathy, which can progress to hypoglycemia, hepatic encephalopathy, and acute renal failure. Untreated it has a mortality of over 80% and to date the only treatment has been retransplantation. As a result of the beneficial effect of Prostaglandin infusion in patients with fulminant hepatic failure, this trial was conducted to determine whether PGE1 would be of value in primary nonfunction. We have encountered 16 cases of primary nonfunction in 94 liver transplants, an incidence of 17%. Initially in the program, there were 6 occurrences of nonfunction that did not receive PGEi; 3 underwent retransplantation (2 survivors), 2 died awaiting another liver, and in one recovery of hepatocellular function occurred with supportive care but the patient died of cytomegalovirus infection. Ten patients received PGE1 within 4—34 hr of transplantation. Within 12 hr of treatment, 8 patients responded with a significant fall in the AST (129 U/hr) whereas, in the untreated group, the AST continued to rise (267±102 U/hr) at the same rate as prediagnosis (337±95 U/hr). At the conclusion of the infusion (4—7 days) in the 8 responders, there were significant decreases in AST (4386±546 U/L to 102±21 U/L), prothrombin time (22± 2 to 12±.4 sec) and partial thromboplastin time (4 5 ± 3 - 2 9± 4 sec), and significant increases in coagulation factor V (26±8 to 95±12%) and factor VII (10±5 to 61± 4%). No serious side effects occurred, although 2 patients developed diarrhea, and abdominal cramps. Two patients treated with PGEX were retransplanted at 1 0 - 36 hr and were considered nonresponders. Graft survival was 80% in the PGEi-treated group and 17% in the untreated group (P<0.05) and patient survival was 90% and 33%, respectively. This study suggests a potential benefit of PGEi in the treatment of primary nonfunction.

AB - Primary nonfunction following orthotopic liver transplantation is characterized by rapidly rising serum transaminases, minimal bile production, and severe coagulopathy, which can progress to hypoglycemia, hepatic encephalopathy, and acute renal failure. Untreated it has a mortality of over 80% and to date the only treatment has been retransplantation. As a result of the beneficial effect of Prostaglandin infusion in patients with fulminant hepatic failure, this trial was conducted to determine whether PGE1 would be of value in primary nonfunction. We have encountered 16 cases of primary nonfunction in 94 liver transplants, an incidence of 17%. Initially in the program, there were 6 occurrences of nonfunction that did not receive PGEi; 3 underwent retransplantation (2 survivors), 2 died awaiting another liver, and in one recovery of hepatocellular function occurred with supportive care but the patient died of cytomegalovirus infection. Ten patients received PGE1 within 4—34 hr of transplantation. Within 12 hr of treatment, 8 patients responded with a significant fall in the AST (129 U/hr) whereas, in the untreated group, the AST continued to rise (267±102 U/hr) at the same rate as prediagnosis (337±95 U/hr). At the conclusion of the infusion (4—7 days) in the 8 responders, there were significant decreases in AST (4386±546 U/L to 102±21 U/L), prothrombin time (22± 2 to 12±.4 sec) and partial thromboplastin time (4 5 ± 3 - 2 9± 4 sec), and significant increases in coagulation factor V (26±8 to 95±12%) and factor VII (10±5 to 61± 4%). No serious side effects occurred, although 2 patients developed diarrhea, and abdominal cramps. Two patients treated with PGEX were retransplanted at 1 0 - 36 hr and were considered nonresponders. Graft survival was 80% in the PGEi-treated group and 17% in the untreated group (P<0.05) and patient survival was 90% and 33%, respectively. This study suggests a potential benefit of PGEi in the treatment of primary nonfunction.

UR - http://www.scopus.com/inward/record.url?scp=0024461605&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024461605&partnerID=8YFLogxK

M3 - Article

C2 - 2675405

AN - SCOPUS:0024461605

VL - 48

SP - 447

EP - 453

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 3

ER -

Greig PD, Woolf GM, Sinclair SB, Abecassis M, Strasberg SM, Taylor BR et al. Treatment of primary liver graft nonfunction with prostaglandin E1 Transplantation. 1989 Jan 1;48(3):447-453.